Dexcom has isolated the problem to “a couple of components of the subcutaneous needle insertion mechanism” and has since increased scrutiny on both incoming supplies and outgoing product, Morgan Stanley analyst Patrick Wood said in a report on Oct. 31. (Shutterstock)
